Therapeutic area intelligence for Primary Aldosteronism with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

AstraZeneca →

Assets

baxdrostat →

SAL0140 →

Recent signals(2)

ClinicalJuly 7, 2026

AstraZeneca's Phase III Trial of Baxdrostat in Primary Aldosteronism Underway

AstraZeneca is conducting Phase III trial to evaluate the efficacy and safety of baxdrostat in patients with Primary Aldosteronism.

ClinicalJune 13, 2026

Phase II Trial of SAL0140 Shows Promise for Primary Aldosteronism

A Phase II clinical trial is underway to evaluate the efficacy and safety of SAL0140 at varying doses in patients with primary aldosteronism.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.